British American Tobacco (NYSE:BTI) 2026 Conference February 18, 2026 11:00 AM ET Company ParticipantsDavid Waterfield - PresidentTadeu Marroco - CEONone - Video NarratorModeratorOkay. Hi, everyone. Thanks for joining us today. It's a pleasure to welcome British American Tobacco to CAGNY this year. Joining us today are Tadeu Marroco, Chief Executive Officer, and David Waterfield, President of Reynolds American. Also, please join me in thanking them for their sponsorship of the lunch following their presenta ...

Core Insights - The tobacco sector is primarily represented by two industry leaders: Altria Group, Inc. and Philip Morris International Inc., each with distinct geographic focuses and strategies to adapt to the evolving nicotine landscape [1][2] Altria Group, Inc. (MO) - Altria focuses on the U.S. market, leveraging its Marlboro brand while expanding into smoke-free alternatives like NJOY and oral nicotine products [2] - In 2025, Altria achieved a 4.4% increase in adjusted earnings per share and returned approximately $8 billion to shareholders through dividends and share repurchases, highlighting its strong cash-flow generation [3] - The smokeable products segment generated over $11 billion in adjusted operating income with margins expanding to 63.4%, demonstrating Altria's pricing power despite a 9.5% decline in domestic cigarette volumes [4][6] - Altria's smoke-free strategy is advancing, with on! brand shipment volumes rising 10.9% in 2025, and plans for a national rollout of on! PLUS to capture growth in the nicotine pouch category [5] - The long-term investment outlook for Altria is challenged by structural and regulatory headwinds, with ongoing volume declines in traditional cigarettes [6] Philip Morris International Inc. (PM) - Philip Morris is transitioning towards smoke-free products, with smoke-free offerings accounting for 41% of total net revenues and 42% of gross profit in Q3 2025, driven by strong performance from IQOS, ZYN, and VEEV [7][8] - The company reported a record quarterly smoke-free gross profit of $3.1 billion, indicating a shift towards a more sustainable profit model [7] - Philip Morris' operational discipline and productivity initiatives have supported margin expansion and earnings growth, despite a 3.2% decline in cigarette shipment volumes in Q3 [10][11] - The reliance on smoke-free products introduces risks, as any slowdown in adoption could impact the ability to offset declines in combustible product volumes [11] Stock Performance and Valuation - Over the past year, Altria's shares increased by 15.9%, underperforming Philip Morris, which surged by 36.5%, and the industry's growth of 38.7% [12] - Altria's forward P/E ratio is 10.7, slightly below its one-year median, while Philip Morris' forward P/E ratio stands at 21.12, above its median [13] - Philip Morris is viewed as a more promising investment due to its diversified international presence and established portfolio of reduced-risk products, while Altria's growth is limited by its heavy exposure to the U.S. cigarette market [16][17]

Philip Morris International Inc. (NYSE:PM) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. Jefferies Sees Limited Re-Rating Upside for Philip Morris (PM) in 2026 On January 20, Jefferies analyst Edward Mundy moved Philip Morris International Inc. (NYSE:PM) to Hold from Buy and cut the firm’s price target to $180 from $220. In his note, he said Jefferies sees limited room for the stock to be re-rated in 2026. The analyst also pointed to tougher competition. He noted that British Amer ...

Core Insights - Altria Group, Inc. has formed an alliance with KT&G to explore international opportunities in modern oral nicotine products, aiming to expand its market presence beyond the U.S. [1][9] - The collaboration includes Altria acquiring a stake in Another Snus Factory, enhancing its product offerings in regions with growing demand for complex flavor profiles [2] - The partnership allows Altria to utilize KT&G's global infrastructure and product development expertise while contributing its strengths in commercialization and brand management [3] - The alliance is a strategic move towards expanding Altria's presence in smoke-free categories globally, as the modern oral market is experiencing rapid growth [4] - Successful execution of this partnership is crucial for Altria to strengthen its position in next-generation products and work towards a smoke-free future [5] Competitive Landscape - Philip Morris International Inc. has established itself as a leader in the smoke-free transition, with smoke-free products contributing 41% of its net revenues in Q3 2025, and its nicotine pouch brand ZYN showing 39% growth [6] - Turning Point Brands, Inc. is also experiencing significant growth, with its Modern Oral portfolio representing nearly one-third of sales and revenues rising 31.2% year-over-year to $119 million in Q3 2025 [7] Financial Performance - Altria's shares have declined by 12.8% over the past month, compared to a 4% decline in the industry [8] - Altria trades at a forward price-to-earnings ratio of 10.46X, lower than the industry average of 14.07X [11] - The Zacks Consensus Estimate indicates year-over-year earnings growth of 6.1% for 2025 and 2.5% for 2026 [12]

Core Insights - Altria Group, Inc. and Philip Morris International Inc. are navigating a transforming tobacco market with distinct strategies, focusing on smoke-free alternatives and maintaining strong brand presence [1][2] Altria Group, Inc. - Altria's pricing power is a key factor in its financial resilience, with a 10% net price realization in smokeable products leading to a 4.2% increase in adjusted operating companies income (OCI) in Q2 2025 [6] - The oral tobacco segment, particularly the on! nicotine pouch brand, saw shipments rise 26.5% year over year, contributing to a 10.9% increase in adjusted OCI [7] - Adjusted earnings per share (EPS) increased 8.3% year over year to $1.44 in Q2 2025, with revenues net of excise taxes at $5.29 billion [8] - Marlboro maintains a 59.5% share in the premium category, showcasing Altria's strong market position and ability to adapt to a smoke-free future [10] Philip Morris International Inc. - Philip Morris's growth is driven by smoke-free products, which accounted for 41% of total net revenues and 42% of gross profit in Q3 2025 [11] - Shipments of IQOS, ZYN, and VEEV showed significant growth, with IQOS shipments up 15.5% to 41 billion units, maintaining a 76% global share in heated tobacco [12] - Adjusted operating income rose 12.4% to $4.7 billion, with adjusted EPS increasing 17.3% to $2.24, supported by strong performance in smoke-free products [13] - Despite a 3.2% decline in cigarette shipment volumes, Philip Morris managed a 4.3% increase in net revenues through pricing strategies [14] Market Performance - Altria's stock has gained 25.3% over the past year, outperforming Philip Morris's 13.1% increase and the broader S&P 500's 20.6% rise [21] - Altria is trading at a forward P/E ratio of 11.41, while Philip Morris's forward P/E ratio stands at 18.24 [20] Investment Outlook - Altria is positioned as a better investment for income-focused investors due to its attractive valuation, robust pricing power, and growing smoke-free momentum, while Philip Morris offers stronger global growth potential [22]

Core Insights - Philip Morris International (PM) reported third-quarter 2025 results that exceeded Zacks Consensus Estimates for both revenue and earnings, reflecting strong growth prospects despite a recent stock correction [1][2] Financial Performance - Adjusted earnings per share (EPS) for Q3 2025 was $2.24, a 17.3% increase year-over-year, surpassing the Zacks Consensus Estimate by 6.67% [3] - Net revenues reached $10.8 billion, marking a 9.4% increase on a reported basis and 5.9% on an organic basis compared to the same quarter last year, with a positive surprise of 1.32% against the consensus estimate of $10.7 billion [4] - Operating income for the quarter was $4.3 billion, reflecting a substantial increase of 16.7% from the previous year [4] Product Shipment and Growth - Total shipment volume of cigarettes and smoke-free products grew by 0.7% year-over-year to 204.9 billion units, driven by a 91.0% increase in E-vapor shipments and a 16.9% rise in Oral smoke-free products [5] - The smoke-free business accounted for 41% of total net revenues, up 2.9 percentage points from the previous year, with a year-over-year growth of 17.7% in its top line and a 19.5% increase in gross profits [6] Future Guidance - For 2025, PM anticipates adjusted EPS in the range of $7.46-$7.56, indicating a growth of 13.5-15.1% from the previous year [7] - The company expects net revenues to increase by 6-8% on an organic basis and operating income to grow by 10-11.5%, alongside a projected smoke-free product volume growth of 12% to 14% [8]

Core Insights - Altria Group, Inc. is focusing on a smoke-free future, with its on! nicotine pouches driving significant growth in the oral tobacco products segment, achieving a retail share of 8.7% in the U.S. [1][8] - The company reported a 26.5% increase in shipment volume, reaching 52.1 million cans in the second quarter of 2025, contributing to substantial profit growth [2][8] - Altria's strategy, executed through its subsidiary Helix, emphasizes aggressive brand-building and emotional connections with adult consumers to maintain momentum in a competitive market [3][4] Market Position and Competition - Philip Morris International Inc. is also advancing in the smoke-free product space, with these products accounting for 41% of total net revenues and over 42% of gross profit in the second quarter of 2025, showing 11.8% shipment growth [5] - Turning Point Brands, Inc. is emerging as a competitor, with its Modern Oral sales increasing nearly eightfold year-over-year to $30.1 million, representing 26% of total revenues [6] Financial Performance - Altria's shares have increased by 15.4% over the past three months, contrasting with a 4.3% decline in the industry [7] - The company trades at a forward price-to-earnings ratio of 12.05X, lower than the industry average of 14.27X [10] - Zacks Consensus Estimate indicates year-over-year earnings growth of 6.1% for 2025 and 2.6% for 2026 [11]

Core Points - Philip Morris International (PMI) U.S. announced a $37 million investment in its manufacturing facility in Wilson, North Carolina, aimed at expanding operations and supporting the company's mission to provide smoke-free alternatives to adult smokers [1][2] - The investment is part of PMI U.S.'s broader "Invested in America" platform, which focuses on increasing U.S. manufacturing and innovation capacity through strategic investments [1][5] - The Wilson facility currently employs over 80 full-time staff and produces HEETS for IQOS 3.0, the only heated tobacco product authorized by the FDA as a modified risk tobacco product [2][3] Investment and Economic Impact - The expansion in Wilson is expected to generate economic activity in the local community and reinforce PMI U.S.'s long-term commitment to American manufacturing [1][2] - PMI U.S. has previously invested hundreds of millions of dollars in U.S. manufacturing and innovation, including a $232 million expansion in Owensboro, Kentucky, and a $600 million investment in Aurora, Colorado, which together will create nearly 1,000 direct jobs [5] Product Development - The Wilson expansion will add a production line for TEREA, consumables for the IQOS ILUMA heated tobacco system, with premarket tobacco product applications submitted to the FDA on October 20, 2023 [4] - IQOS 3.0 is currently being commercialized in select locations, including Austin, Texas, and Jackson, Mississippi, as well as on military bases [4]

Core Insights - The tobacco sector presents two main investment options: Altria Group, Inc. and Philip Morris International Inc., each with distinct market strategies and growth trajectories towards a smoke-free future [1][2] Altria Group, Inc. - Altria focuses on the U.S. market, leveraging its Marlboro brand while expanding into alternatives like NJOY and oral nicotine pouches [2] - The company achieved a 10.8% net price realization in smokeable products in Q1 2025, contributing to a 2.7% increase in adjusted operating income [3][9] - Altria's oral nicotine pouch brand, on!, saw an 18% increase in shipments, capturing 8.8% of the oral tobacco category and 17.9% of the nicotine pouch segment [4][9] - Despite setbacks in the e-vapor category, Altria is refining its product pipeline and advocating for regulatory reforms to combat the rise of illicit disposable e-vapor products, which account for over 60% of the U.S. market [5] - The cigarette industry faces challenges, with shipment volumes declining due to macroeconomic pressures and the growth of illegal e-vapor products, impacting low-income smokers [6] Philip Morris International Inc. - Philip Morris is advancing its transformation strategy with a strong smoke-free portfolio, including IQOS, ZYN, and VEEV, and has approximately 41.5 million adult users by Q2 2025 [7][9] - IQOS is the primary driver of growth, with accelerated adoption in key markets supported by commercial initiatives and product innovations [8][10] - The company offers smoke-free products in 97 markets, with nearly half providing multiple product categories, enhancing its global reach [10] - Philip Morris faces challenges such as currency volatility and increasing regulatory risks, particularly regarding nicotine pouch marketing [11] Financial Performance and Valuation - Altria's forward P/E ratio is 10.96, appealing to income-focused investors, while Philip Morris has a higher multiple of 20.12, reflecting its global presence and momentum in smoke-free products [15] - Over the past month, Altria gained 2.1%, while Philip Morris dropped 11.6%, underperforming the S&P 500's 3.4% rise [14] Conclusion - Philip Morris is better positioned for long-term growth with its aggressive pivot towards a smoke-free future and strong global traction, while Altria's focus on domestic stability and pricing strength supports income-focused investors but faces more headwinds [16]

Core Viewpoint - Philip Morris International Inc. is expected to report growth in both revenue and earnings for the second quarter of 2025, with earnings anticipated to be released on July 22, before market opening [1]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues is approximately $10.3 billion, reflecting an 8.3% increase from the same quarter last year [2]. - The consensus estimate for quarterly earnings has risen to $1.85 per share, indicating a 16.4% increase compared to the previous year [2]. Earnings Performance and Predictions - Philip Morris has a trailing four-quarter average earnings surprise of 3.6%, with the last quarter's earnings exceeding the Zacks Consensus Estimate by 5% [3]. - The company has an Earnings ESP of -0.04% and a Zacks Rank of 2 (Buy) [4]. Factors Influencing Q2 Earnings - Strong pricing strategies have been a significant driver of revenue and operating income growth, as smokers tend to accept price increases due to the addictive nature of cigarettes [5]. - Smoke-free products contributed to 44% of the gross profit in Q1 2025, highlighting the success of the IQOS ILUMA device and other innovations like ZYN nicotine pouches and VEEV ONE e-vapor [6]. Smoke-Free Product Growth - The Zacks Consensus Estimate for total smoke-free product revenues for Q1 is $4,225.9 million, up from $3,530 million in the previous year [7]. - Management anticipates a 10% growth in IQOS HTU adjusted IMS for Q2, with ZYN shipments expected to maintain levels from Q1 [8]. Earnings Forecast - The company forecasts adjusted earnings between $1.80 and $1.85 for Q2, including a favorable currency impact of 6 cents per share [9][11]. Stock Performance - Philip Morris shares have increased by 9.7% over the past three months, underperforming the Zacks industry growth of 10.2% but lagging behind the S&P 500's 19.5% increase [12]. - Compared to major tobacco players, Philip Morris outperformed Altria but was outpaced by Turning Point Brands and British American Tobacco [13]. Valuation Analysis - Philip Morris is trading at a premium with a forward 12-month price-to-earnings ratio of 22.39X, above the industry average of 15.21X [15]. - Despite the premium valuation, the company's growth profile and strategic transformation make it an attractive option for investors [16].